Evolve BioSystems, Inc. is a privately-held infant health company dedicated to discovering and implementing microbiome-based solutions that recognize how infant diet and microbiome interact to improve short and long-term health of infants worldwide.

Building on more than a decade of research exploring the unique relationship between ancestral bacterial strains largely eradicated from infants in developed nations and human breast milk, Evolve has pioneered an innovative strategy to transform infant health.

Evolve has built substantial science and technology assets to address underlying gut function that may be the root cause of acute and chronic health conditions. We envision a future where non-communicable diseases such as type 1 diabetes, atopic dermatitis, food allergies, and NEC are eliminated through careful attention to the development of the infant gut microbiome in the first 100 days.

 
A Changing Gut Microbiome
Dysbiosis of the Newborn Gut
Consequences of Dysbiosis
The Evolve Approach
 

CAREERS

Check out our open positions.

 
Featured
Evolve Sets Stage for Strategic Growth with Appointment of Kaile Zagger as New Chief Executive Officer

Healthcare expert brings deep transformational leadership and 20+ years of experience to accelerate and advance Evolve's groundbreaking work

Data Suggests That B. infantis EVC001 Improves Preterm HMO Utilization

Study published in Frontiers in Pediatrics builds strain-specific evidence regarding the safety and tolerability of activated B. infantis EVC001

New research is first to show how key gut bacterium trains infant immune system

Study published in cell reveals critical role of activated B. infantis EVC001 in using human milk to program immune cells early in life to control inflammation and autoimmune disease risk

New study reports reductions in diaper rash and colic as well as improvement in sleep in infants following supplementation with the specific gut bacterium activated B. infantis EVC001

Researchers publishing today in the peer-reviewed science journal Beneficial Microbes reported that three common infant health issues associated with Newborn Gut Deficiency – diaper rash, colic and sleep problems – were substantially reduced or eliminated altogether within days of introducing a key beneficial gut bacterium that is missing in more than 90% of all babies in the U.S.

Investors Continue to Support Breakthrough Research on Infant Gut Health

Evolve's final round of funding will help further the brand's goal of resolving Newborn Gut Deficiency in the U.S

New study reports activated B. infantis EVC001 improves health outcomes in preterm infants

Study quantifies unprecedented reduction in enteric inflammation, diaper rash and antibiotic use via beneficial gut remodeling